Abstract
Alzheimer’s disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined “frail”. At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify “the frail AD”. To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered “frail” among AD.
Keywords: Alzheimer’s disease, frailty, tau protein, amyloid-β42, mini mental state examination.
CNS & Neurological Disorders - Drug Targets
Title:Frailty Among Alzheimer’s Disease Patients
Volume: 12 Issue: 4
Author(s): Giacomo Koch, Lorena Belli, Temistocle Lo Giudice, Francesco Di Lorenzo, Giulia Maria Sancesario, Roberto Sorge, Sergio Bernardini and Alessandro Martorana
Affiliation:
Keywords: Alzheimer’s disease, frailty, tau protein, amyloid-β42, mini mental state examination.
Abstract: Alzheimer’s disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined “frail”. At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify “the frail AD”. To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered “frail” among AD.
Export Options
About this article
Cite this article as:
Koch Giacomo, Belli Lorena, Giudice Lo Temistocle, Lorenzo Di Francesco, Sancesario Maria Giulia, Sorge Roberto, Bernardini Sergio and Martorana Alessandro, Frailty Among Alzheimer’s Disease Patients, CNS & Neurological Disorders - Drug Targets 2013; 12 (4) . https://dx.doi.org/10.2174/1871527311312040010
DOI https://dx.doi.org/10.2174/1871527311312040010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Contrast Media in Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Current Problems with Non-Specific COX Inhibitors
Current Pharmaceutical Design Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets Fabrication and Physicochemical and Medicinal Characterization of Nano Traditional Chinese Medicine
Recent Patents on Engineering Ranolazine : Effects on Ischemic Heart
Recent Patents on Cardiovascular Drug Discovery Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Synthesis, Single Crystal Study, in silico Analysis, in vitro Antiinflammatory and Anticancer Activities of 7-hydroxy-14H-naphtho[2,3- a]phenothiazine-8,13-dione
Drug Delivery Letters A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design The Impact of Diabetes on Mortality Among Elderly Patients Admitted for Treatment at a Hospital for Cardiovascular Disease in Southern Brazil
Current Diabetes Reviews Cardiovascular Remodeling Induced by Passive Smoking
Inflammation & Allergy - Drug Targets (Discontinued) HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research